ImmunoCellular Therapeutics' Resemblance to Dendreon - At a Fraction of the Cost [View article]
Over 60,000,000 shares fully diluted 9/30/2010
Common stock to be outstanding after the offering
49,249,211 (1) (2) (3)
item #2 (2) Does not include 11,009,996 shares of common stock issuable upon the exercise of outstanding options (with exercise prices ranging from $0.15 to $1.35 per share) and 2,088,173 warrants (with exercise prices ranging from $1.15 to $1.50).
ImmunoCellular Therapeutics: Clinical and Operational Goals On-Track [View article]
In their last filing IMUC indicated they had funding that would last at least thru the second quarter 2011. Considering outstanding warrants there would be 50 million plus shares fully diluted. It would be encouraging to see a lot of the warrants exercised to fund a phase II trial ending in 2014.
Good Science, and good genes in Cedar Sinai and UPENN. Need good financial managment to attract investors.
ImmunoCellular Therapeutics CEO Explains Economic Significance of New Vaccine Manufacturing Method [View article]
Dr. Garza, ImmunoCellular is making early impressive advances in treatment of glioblastoma, while controlling the cost. Are they going to be able to use the new vaccine production process in the phase II trial?
The Short Case for Green Mountain Coffee Roasters [View article]
The whole pot pouch to throw in your current coffee maker? I'm thinking Starbucks and the rest are afraid of killing the single serve cash cow at this point. Love the whole pot pouch when offered at hotels. The single serve seems to have taken a quick path to oblivion at the hotels. I know it has at my home.
GMCR, so much debt taken on to preserve a patent that has a small patent moat protecting it from competition in the first place. Why billions in debt to protect that short lived moat? I think your article does an excellent job of exposing the attempt to build a coffee novelty bubble and sell it to the public.
As you said, beware that buyout rumor. For me, short the buyout rumor pops.
Treasury's Astonishing Statement on U.S. Default [View article]
"Wolin really seems to be saying here that Illinois has already defaulted, since it’s late on many payments it’s legally obliged to make. And that a late Social Security check is just as bad in terms of America’s creditworthiness as a missed bond payment — even if Treasury is making all of its payments to the Social Security trust fund in a timely manner."
While true, the states are going to be OK until they can't honor bond holders. The Fed is isn't ever going BK, it has a printing machine and an entitlement hugging public that will make sure it prints out their checks and thus debt holders. Inflate the untenable debt bomb away is always possible. Isn't that our policy?
ImmunoCellular Therapeutics: Clinical and Operational Goals On-Track [View article]
Presentation at ASCO (2Q, 2011) ?
I've tried to verify this presentation. Looks like a very questionable claim:
Each First Author will receive a letter of notification via e-mail from the Committee regarding its decision on the abstract in late March. Each First Author of a Late-breaking Abstract will receive a letter of notification regarding the final decision in mid-April. chicago2011.asco.org/C...
Radient Positioned Well With India Cancer Kit Order and AMEX Debt Swap Approval [View article]
Gaur Diagno, anyone familiar with this one. A quick google turns up some part time jobs listed. $400 wholesale price for kits. Price in a third world country after markup? They may go "nationwide"? Are we talking Gaurillions $ of sales yearly?
It would be nice to have Seeking Alpha do a little background on who is pumping and who is offering serious discussion.
IF they have good news on phase II the drug will be sold. Good phase II news is when drugs with solid phase II drugs that work in attractive markets are usually sold.
Huge market potential, so really good news will magnify the reaction.
Why we are Short Rubicon Technologies, Here's the News [View instapost]
A second look? Rubicon has peformed well and even announed a $72 million 6-inch wafer contract. The beats rising quarterly estimates while continuing to raise forward estimates. In addition the that demand for Rubicon's wafer supply is holding up while the LED sector is suffering. The sector does seems to be moving to the larger wafer and it looks possible the continued demand for Rubicon's wafer is saying something about a superior wafer quality or economics?
The Altucher Effect [View article]
Press Release: Trovagene, Inc. – Mon, Jun 25, 2012 6:00 AM EDT
The stock ran up nicely. Did you sell any of your shares?
NANO did the same thing. Did you sell?
PIP just look dead in the water. Any update? Have you sold your shares in PIP?
Fibrocell Science: Interest Increasing With Wednesday's FDA Action [View article]
Patient satisfaction must have been a problem? Why d/c?
ImmunoCellular Therapeutics' Resemblance to Dendreon - At a Fraction of the Cost [View article]
Common stock to be outstanding after the offering
49,249,211 (1) (2) (3)
item #2
(2) Does not include 11,009,996 shares of common stock issuable upon the exercise of outstanding options (with exercise prices ranging from $0.15 to $1.35 per share) and 2,088,173 warrants (with exercise prices ranging from $1.15 to $1.50).
secfilings.nasdaq.com/...=
Seeking Alpha? There are some authors worth following, a lot of pump and dump to beware of.
ImmunoCellular Therapeutics' Resemblance to Dendreon - At a Fraction of the Cost [View article]
Odd, Seeking Alpha puts out an article on this one almost daily???
ImmunoCellular Therapeutics: At the Forefront of Brain Tumor Treatment [View article]
ImmunoCellular Therapeutics: Clinical and Operational Goals On-Track [View article]
Good Science, and good genes in Cedar Sinai and UPENN. Need good financial managment to attract investors.
ImmunoCellular Therapeutics CEO Explains Economic Significance of New Vaccine Manufacturing Method [View article]
ImmunoCellular is making early impressive advances in treatment of glioblastoma, while controlling the cost. Are they going to be able to use the new vaccine production process in the phase II trial?
ImmunoCellular Therapeutics: Clinical and Operational Goals On-Track [View article]
Was this a simple error?
The Short Case for Green Mountain Coffee Roasters [View article]
The single serve seems to have taken a quick path to oblivion at the hotels. I know it has at my home.
GMCR, so much debt taken on to preserve a patent that has a small patent moat protecting it from competition in the first place. Why billions in debt to protect that short lived moat? I think your article does an excellent job of exposing the attempt to build a coffee novelty bubble and sell it to the public.
As you said, beware that buyout rumor. For me, short the buyout rumor pops.
Treasury's Astonishing Statement on U.S. Default [View article]
While true, the states are going to be OK until they can't honor bond holders. The Fed is isn't ever going BK, it has a printing machine and an entitlement hugging public that will make sure it prints out their checks and thus debt holders. Inflate the untenable debt bomb away is always possible. Isn't that our policy?
Interesting article.
ImmunoCellular Therapeutics: Clinical and Operational Goals On-Track [View article]
I've tried to verify this presentation. Looks like a very questionable claim:
Each First Author will receive a letter of notification via e-mail from the Committee regarding its decision on the abstract in late March. Each First Author of a Late-breaking Abstract will receive a letter of notification regarding the final decision in mid-April.
chicago2011.asco.org/C...
Radient Positioned Well With India Cancer Kit Order and AMEX Debt Swap Approval [View article]
It would be nice to have Seeking Alpha do a little background on who is pumping and who is offering serious discussion.
Xoma Rally Not a Surprise [View article]
Huge market potential, so really good news will magnify the reaction.
Why we are Short Rubicon Technologies, Here's the News [View instapost]
The sector does seems to be moving to the larger wafer and it looks possible the continued demand for Rubicon's wafer is saying something about a superior wafer quality or economics?
Back to Overbought [View article]